Zoetis Named One of Most Innovative Companies in 2022 by Fast Company
March 09 2022 - 8:00AM
Business Wire
Recognized for Purpose-driven Innovation in
Donating COVID-19 Vaccine for Animals to Zoos
Zoetis has been named to Fast Company’s list of Most Innovative
Companies for 2022, ranking eighth in the corporate social
responsibility category. Zoetis is the only stand-alone animal
health company to be included on this year’s list which honors
businesses that are making the biggest impact on their industries
and culture as a whole—ultimately thriving in today’s ever-changing
world. These companies are creating the future today with some of
the most inspiring accomplishments of the 21st century. In addition
to the World's 50 Most Innovative Companies, 528 organizations are
recognized across 52 categories.
The recognition is based on Zoetis’ discovery, development and
donation of more than 11,000 doses of its COVID-19 vaccine,
developed uniquely for animals, to more than 70 zoos, as well as
more than a dozen conservatories, sanctuaries, academic
institutions and government organizations, located across the
United States in 2021. The vaccines helped protect great apes,
lions, tigers, bears and other animals known to be susceptible to
SARS-CoV-2 (the virus that causes COVID-19). The vaccine deployment
followed Zoetis’ response in January 2021 to a request from the San
Diego Zoo following confirmed cases of COVID-19 in the gorillas at
the San Diego Zoo Safari Park. The zoos’ use of the vaccine has
been authorized on a case by case basis by the United States
Department of Agriculture (USDA) and the appropriate state
veterinarians. Zoetis has since committed to donating more than
16,000 additional doses of its vaccine to additional zoos and
sanctuaries in the U.S. and other countries.
“We believe healthier animals help create a healthier world, and
we are committed to using our expertise in animal health to help
solve sustainability challenges facing animals and people,” said
Robert J. Polzer, PhD, Executive Vice President and President,
Research and Development at Zoetis. “The COVID-19 pandemic not only
highlighted the important connection between animal health and
human health, but it also demonstrated the need to be ready with
solutions that can help prevent, detect and treat disease in human
and animal health as part of a One Health approach.”
According to the World Organization for Animal Health (OIE), 75%
of emerging infectious diseases have an animal origin. With that in
mind, one of the company’s goals within its Driven to Care
long-term sustainability initiative is to combat diseases that pose
the greatest risk to animals and humans. Through its Center for
Transboundary and Emerging Diseases (CTED), Zoetis has developed
vaccines for high-impact emerging diseases around the world,
including Avian Influenza, Porcine Epidemic Diarrhea Virus,
Schmallenberg Virus, Hendra Virus and Canine Influenza. The Center
continues to work on vaccines for Foot and Mouth Disease and
African Swine Fever. Through the CTED, Zoetis is monitoring
approximately 200 diseases identified by the WHO as zoonotic,
including Avian Influenza, Rabies, Lyme disease, West Nile Virus
and SARS-CoV-2.
“As we live our purpose at Zoetis to nurture the world and
humankind by advancing care for animals, we are committed to
helping create a healthier future for our communities, animals and
the planet we share,” said Jeannette Ferran Astorga, Executive Vice
President, Corporate Affairs, Communications and Chief
Sustainability Officer at Zoetis. “We have a long history of
supporting zoo veterinarians and the animals in their care, and we
are proud that our scientists’ vaccine is helping zoo veterinarians
protect their animals from COVID-19.”
In other recognitions of its progress on sustainability, Zoetis
was named one of Newsweek’s Most Responsible Companies for 2022 and
was included in Investor’s Business Daily’s 100 Best ESG Companies.
In 2021, the company announced its Driven to Care long-term
sustainability strategy and goals followed by its first
Sustainability Report. Zoetis will continue to share updates on its
sustainability activities, including progress against its Driven to
Care goals, and report annually.
About Zoetis
As the world’s leading animal health company, Zoetis is driven
by a singular purpose: to nurture our world and humankind by
advancing care for animals. After 70 years innovating ways to
predict, prevent, detect, and treat animal illness, Zoetis
continues to stand by those raising and caring for animals
worldwide -- from livestock farmers to veterinarians and pet
owners. The company’s leading portfolio and pipeline of medicines,
vaccines, diagnostics and technologies make a difference in over
100 countries. A Fortune 500 company, Zoetis generated revenue of
$7.8 billion in 2021 with approximately 12,100 employees. For more
information, visit www.zoetis.com.
Forward-Looking Statements: This
press release contains forward-looking statements, which reflect
the current views of Zoetis with respect to: business plans or
prospects; ESG commitments, goals and aspirations; R&D
commitments; and other future events. These statements are not
guarantees of future performance or actions. Forward-looking
statements are subject to risks and uncertainties. If one or more
of these risks or uncertainties materialize, or if management's
underlying assumptions prove to be incorrect, actual results may
differ materially from those contemplated by a forward-looking
statement. Forward-looking statements speak only as of the date on
which they are made. Zoetis expressly disclaims any obligation to
update or revise any forward-looking statement, whether as a result
of new information, future events or otherwise. A further list and
description of risks, uncertainties and other matters can be found
in our Annual Report on Form 10-K for the fiscal year ended
December 31, 2021, including in the sections thereof captioned
“Forward-Looking Statements and Factors That May Affect Future
Results” and “Item 1A. Risk Factors,” in our Quarterly Reports on
Form 10-Q and in our Current Reports on Form 8-K. These filings and
subsequent filings are available online at www.sec.gov,
www.zoetis.com, or on request from Zoetis.
All trademarks are the property of Zoetis Services LLC or a
related company or a licensor unless otherwise noted.
© 2022 Zoetis Services LLC. All rights reserved.
ZTS-COR ZTS-IR
View source
version on businesswire.com: https://www.businesswire.com/news/home/20220309005537/en/
Media Contacts: Christina Lood
1-973-822-7249 (o) christina.lood@zoetis.com Bill Price
1-973-443-2742 (o) william.price@zoetis.com Investor Contact: Steve Frank 1-973-822-7141 (o)
steve.frank@zoetis.com
Zoetis (NYSE:ZTS)
Historical Stock Chart
From Jun 2024 to Jul 2024
Zoetis (NYSE:ZTS)
Historical Stock Chart
From Jul 2023 to Jul 2024